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Billions of doses of medicines are donated for mass drug administrations in support of the World Health Organization’s 
“Roadmap to Implementation,” which aims to control, eliminate, and eradicate Neglected Tropical Diseases (NTDs). 
The supply chain to deliver these medicines is complex, with fragmented data systems and limited visibility on 
performance. This study empirically evaluates the impact of an online supply chain performance measurement system, 
“NTDeliver,” providing understanding of the value of information sharing towards the success of global health 
programs. 
Methods 
Retrospective secondary data was extracted from NTDeliver, which included 1,484 shipments for four critical 
medicines ordered by over 100 countries between February 28, 2006 and December 31, 2018. We applied statistical 
regression models to analyze the impact on key performance metrics, comparing data before and after the system was 
implemented. 
Findings 
The results suggest information sharing has a positive impact on three performance indicators: purchase order timeliness 
(β=1.01, p<0.000), arrival timeliness (β=0.53, p=0.09), and—most importantly—delivery timeliness (β=0.73, p=0.03). 
Three variables indicated an increased positive impact when the data is publicly shared: shipment timeliness 
(β=2.57, p=0.001), arrival timeliness (β=2.88, p=0∙003), and delivery timeliness (β=2.82, p=0.01).
Conclusions
Our findings suggest that information sharing between the NTD program partners can help drive improved performance 
in the supply chain, and even more so when data is shared publicly. Given the large volume of medicine and the 
significant number of people requiring these medicines, information sharing has the potential to provide improvements 
to global health programs affecting the health of tens to hundreds of millions of people
Author Summary 
The supply chain to deliver donated preventive chemotherapy medicines is complex due to the many stakeholders and 
partnerships participating, as well as challenging because the logistics are further complicated by delivery to remote 
destinations in developing countries. As MDA campaigns involve treating hundreds of thousands to millions of patients 
in endemic regions within entire countries over the course of days or weeks, close coordination and timing of medicine 
delivery is critical. Inefficiencies caused by fragmented data systems and limited transparency on supply chain 
performance further challenges the ability to identify shipment issues and explore the root cause of the issues. Prior to 
2016, delivery was performing below standards, lagging as much as 40% below the WHO target of 80% on-time 
delivery. These delays result in wasted medicine donations, increased program costs, delayed MDAs, or sometimes even 
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completely missed MDAs. In September 2016, an online supply chain performance measurement system, “NTDeliver,” 
was launched by the NTD Supply Chain Forum (a public-private partnership focused on managing and improving the 
PC donation supply chain) to enhance supply chain performance and information transparency. Our findings suggest that 
information sharing through NTDeliver is positively associated with performance at several key stages in NTD supply 
chain and that information sharing has more substantial positive impact on performance when the information is made 
publicly accessible, focused towards country program managers. The study findings support investment in supply chain 
systems and commitment to data transparency, in the context of a growing focus on supply chain investment in NTD 
programs.
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Introduction
Public-private partnership programs provide medicines for preventive chemotherapy (PC) through mass drug 
administration (MDA) campaigns to more than one billion people annually. The programs are sustained by large-scale 
donations from major pharmaceutical companies in support of the World Health Organization’s 2012 “Roadmap to 
Implementation,” which outlined global strategies and 2020 targets to control, eliminate, and eradicate Neglected 
Tropical Diseases (NTDs) [1]. While significant progress was made towards these 2020 targets, the WHO has recently 
released a new NTD roadmap with 2030 targets, which pharmaceutical manufacturers have committed to continuing 
to support [2]. As of January 2020, 15 billion doses of medicines were donated towards these PC-NTD programs [3]. 
The donations from pharmaceutical companies are what makes these the world’s largest and most successful public 
health programs [4]. MDA campaigns are comprised of once or twice-a-year treatment with one or more medicines 
at the community level that bring together a number of stakeholders, requiring considerable coordination as they 
typically involve treating hundreds of thousands to millions of patients in endemic regions within entire countries over 
the course of days or weeks [5].
The logistics involved to make these medicines available to support MDAs is both critical and complex, due to the 
importance of meeting the targeted treatment date and the many stakeholders and partnerships involved. Fig 1 provides 
an overview of the processes involved and performance measures associated with each link in the supply chain. For the 
MDA campaigns, there are considerable resources and coordination involved within a narrow timeframe, which thereby 
increases the criticality of on-time delivery. However, inefficiencies caused by fragmented data systems and a lack of 
visibility to supply chain performance have resulted in substandard performance for on-time delivery of medicine to in-
country central medical stores. Sometimes delivery targets may lag as much as 40% below the WHO target for 80% of 
all shipments to be delivered at least one month before the planned MDA date [6]. Delivery delays result in waste, 
increased program costs, and delayed or even completely missed MDAs, leaving individuals susceptible to NTD 
infections [7].
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Fig 1. Components of the NTD supply chain from application for donation to in-country delivery to central 
medical stores. 
To improve the efficiency and performance of NTD supply chain, the NTD Supply Chain Forum was established in 
2012 [3]. The NTD Supply Chain Forum includes the following partners: the WHO, the Bill and Melinda Gates 
Foundation, six pharmaceutical donors (GlaxoSmithKline, Merck & Co. Inc., Merck KGaA, Pfizer, Johnson & 
Johnson, and Eisai), logistics partner DHL, and non-governmental organizations (NGOs) - the International 
Trachoma Initiative, Children Without Worms, the Mectizan® Donation Program, and RTI International [3].  
Subsequently to the formation of this forum, “NTDeliver,” a centralized information system, was launched in 2016 
by the NTD Supply Chain Forum to share data from various partners along supply process chain as means of 
facilitating performance information sharing [8]. Through NTDeliver, all stakeholders in the supply chain—and even 
the general public—may access performance metrics on all shipments of the four medicines that participate in data 
sharing through NTDeliver.
Information sharing in the context of supply chains— “the extent to which crucial and/or proprietary information is 
available to members of the supply chain”—is an integral aspect of performance management and the sharing of 
accurate and timely information has been linked to supply chain performance improvements [9,10]. Many studies 
have been conducted on the value of information sharing to improve supply chain performance in the private sector. 
Information sharing has been proven to have a range of benefits, from improved resource utilization to reduced cycle 
Application and 
Order
• Process: application/order finalized at country/regional level; WHO HQ raises purchase order to the manufacturer
• Performance measure: timely submission of application against dates; timely purchase order issue (six months prior to 
Mass Drug Administration – MDA)
• Involved partners: Ministry of Health/NTD coordinator, WHO, pharmaceutical manufacturers 
Manufacturing
• Process: pharmaceutical manufacturers produce medications and package existing stock for shipment
• Performance measure: packing timeliness - no specific standard
• Involved partners: WHO, pharmaceutical manufacturers, third party logistics service providers, supporting non-
governmental organizations
Shipment
• Process: "go signal" obtained from WHO to initiate shipment; shipped by air, sea, or land
• Performance measure(s): go signal timeliness (actual date against request date); timely shipment (three months prior to 
MDA)








• Process: shipment arrives in country, clears customs, delivered to central medical store; medicines will be distributed to 
district hospitals, health outposts, or program campaigns to be distributed via MDAs
• Performance measure(s): arrival timeliness - no specific standard; delivery to central medical store one month in advance 
of MDA
• Involved partners: WHO, pharmaceutical manufacturers, third party logistics service providers, customs agents, supporting 
non-governmental organizations, Ministry of Health/NTD coordinator, 
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time between order and delivery [11]. These benefits stem from the increased transparency that enable risks to be 
anticipated and shared among supply chain partners, which strengthens coordination to achieve optimal operational 
performance [11-13]. Largely, this body of literature with empirical studies investigates the value of information 
sharing in a commercial supply chain focused on a dyadic relationship, primarily between two partners, a buyer and 
a supplier [14].
Despite the growing importance of supply chain initiatives in the global NTD agenda, there is limited research 
dedicated to exploring measures to improve NTD supply chain performance nor the impact of information sharing. 
This limitation may be an indicator that performance measurement and management systems have not been widely 
developed and systematically implemented as part of the overall humanitarian supply chain strategy [15].  Only 
Korpoc’s 2015 research on the impact of the NTD “first mile” processes (the segment of the NTD supply chain 
covering up to delivery to central medical stores) on MDA timeliness acknowledges this area of NTD supply chain 
performance measurement by identifying the need for performance indicators and outlining suggested metrics [7]. 
Furthermore, the recent COVID-19 pandemic has raised the profile both of the criticality of publicly sharing timely 
data in the global health domain and the topic of assuring robust supply chains to meet global health goals [16-21]. 
Thus, the timing could not be better to study information sharing and supply chain management in the wider global 
humanitarian health context.
This study seeks to evaluate empirically the impact of information sharing via NTDeliver on supply chain 
performance—improvements which ultimately contribute to achieving the global NTD targets. We examine the 
following two research questions: 1) what is the impact of information sharing through NTDeliver on the 
performance of the NTD PC medicines donation supply chain? and 2) what is the impact on the performance when 
country-level data is made publicly accessible? We use data obtained from the NTD Supply Chain Forum and 
implement regression models on these research questions. We find that information sharing has a positive impact on 
three performance indicators of the NTD supply chain: purchase order timeliness, arrival timeliness, and delivery 
timeliness. Furthermore, when country-level information sharing is made publicly accessible, more substantial impact is 
observed primarily on the downstream indicators, with positive impact observed on shipment timeliness, arrival 
timeliness, and delivery timeliness. 
Methods
Study design and scope
We used retrospective data from NTDeliver that are routinely collected from and managed by supply chain partners 
supporting delivery of PC medicines to central medical stores. Permission was granted to use this data by the NTD 
Supply Chain Forum. The data is derived from vetted, existing data sources managed by NTD supply chain partners, 
such as:
 WHO Preventive Chemotherapy and Transmission databank
 Data provided to WHO country offices by the countries’ Ministry of Health through the joint application 
process to request donations
 Purchase orders raised by the WHO headquarters 
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 Shipping documents generated by logistics service providers, in partnership with pharmaceutical donors
The data represents shipments of four medicines from four manufacturers to treat three different diseases, accounting for 
almost 11.5 billion doses of PC medicines to 103 recipient countries covering 1,484 total shipments from February 28, 
2006, to December 31, 2018. The data is refreshed and uploaded from these various sources daily [22].
While there are numerous medicines for NTDs donated by various pharmaceutical manufacturers for the NTDs, this 
research’s scope focuses on PC medicines donations managed by the WHO through the “joint application package” 
(JAP) established in 2013, which supports an integrated review and subsequent reporting on medicines usage.23 The 
JAP streamlines the application for  donation of multiple medicines, especially as medicines are co-administered 
where diseases are co-endemic [23]. These PC medicines include: diethylcarbamazine citrate, albendazole, 
mebendazole, and praziquantel [24]. This focus is justified by the considerable volume of medicines, the unique 
nature of this supply chain that includes WHO involvement, the importance of PC to achieve NTD targets, and 
accessibility of data through NTDeliver. There are opportunities to improve processes across the supply chain but the 
focus of this research will be on the segment from application to delivery to central medical stores, also referred to 
by partners as the “first mile” [7]. We chose to focus on the first mile due to the WHO drive to improve on-time 
delivery to central medical stores, the accessibility of relevant data, and opportunity to leverage information sharing 
among the many partners involved in this segment. Central medical stores (CMS) (most commonly utilized in Africa, 
Asia, and Latin America) serve as a warehouse and administrative facility that receives, stores, and manages medical 
supplies for national health programs and initiatives and are generally leveraged for humanitarian stock.6,25 Improving 
the on-time delivery of PC medicine to the CMS is critical to the downstream in-country distribution to program sites 
where they are needed [6].
Variables 
The variables for this analysis are various key performance indicators (KPIs), which are actively reviewed through 
the NTD Supply Chain Forum and of interest to the supply chain partners, including the WHO. The most critical 
KPI is delivery timeliness, by which the WHO evaluates performance of this first mile of the NTD supply chain [6]. 
Both the independent and dependent variables were created from the data in the system, reflecting the KPIs and 
benchmarks standards tracked by the NTD Supply Chain Forum partners. Table 1 summarizes the key variables in 
the analysis.
Confounding factors, incorporated via control variables, were included in the analyses to explore whether the 
relationship of the independent and dependent variables is skewed or invalidated by other confounding factors. The 
controls for medicine and disease were chosen with consideration to the fact that the medicines are produced by 
different manufacturers for different disease programs, which may lend itself to some variability in the supply chains. 
The region was also included as a control since performance may vary according to the destination – shipment routes 
and customs clearance processes vary according to the destination. Mode of shipment was incorporated as a control 
since the shipment speed varies between air, land, and sea. Finally, although the supply chain process is the same 
regardless of order size, larger orders could take more time to prepare and smaller orders are often shipped by air, 
making this also a necessary factor to control. 
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Variable type Label Characteristics/description 
NTDeliver Binary (or dichotomous) variable distinguishing whether the donation order has 
been tracked in NTDeliver
Independent  
NTDeliver public access Binary (or dichotomous) variable distinguishing whether country-level was 
publicly accessible in NTDeliver
PO timeliness Continuous variable measuring the timeliness of the Purchase Order (PO) provided 
by the WHO HQ to initiate the order for the pharmaceutical donation; measured in 
months
Go signal timeliness Continuous variable approval from the WHO for the order to be shipped, once the 
needed documentation is prepared; calculated by finding the number of days 
between go signal request date and go signal approval date; measured in days
Shipment timeliness Continuous variable measuring the timeliness of the order being shipped from the 
manufacturing site; calculated by finding the number of months between the 
shipment date and the MDA; measured in months
Arrival timeliness Continuous variable measuring the timeliness of the arrival of the shipment into 
the country; calculated by finding the number of months between the arrival date 
and the MDA; measured in months
Dependent
Delivery timeliness Continuous variable measuring the timeliness of the shipment’s arrival to the 
delivery warehouse; calculated by finding the amount of time between the delivery 
date and the MDA; measured in months
Order size Continuous variable which identifies number of tablets ordered; segmented into 
three groups: ≥10M; <10M and ≥1M; <1M
WHO region Categorical variable which identifies the WHO region the ordering country is 
associated with ; regions include Regional Office for Africa (AFRO), Regional 
Office for the Americas (AMRO), Regional Office for the Eastern Mediterranean 
(EMRO), Regional Office for Europe (EURO), Regional Office for Southeast Asia 
(SEARO), Regional Office for the Western Pacific (WPRO)
Type of medicine Categorical variable which identifies the specific donated medicine ordered; four 
medicines included: albendazole (ALB), diethylcarbamazine citrate (DEC), 
mebendazole (MEB) and praziquantel (PZQ); each specific medicine is associated 
with one pharmaceutical manufacturer, but may be used to treat more than one 
disease
Mode of shipment Categorical variable which identifies the mode of shipment for the given order; 
one of three modes identified for each order: air, sea, or land
Control
Disease treated Categorical variable which identifies the disease(s) the medicine is used to treat; 
three diseases included: lymphatic filariasis (LF), schistosomiasis (SCH), or soil-
transmitted helminthiases (STH)
Table 1. Variable definitions.
Statistical analysis
A quasi-experiment design, using a “one-group pretest-posttest design without control group,” was chosen as 
NTDeliver was implemented in a real-world application that did not roll out the system in a phased approach, barring 
any ability to conduct randomization. This design was used to leverage historical data available on performance to 
understand the impact of this intervention. An ordinary least squares (OLS) regression model was used to review the 
relationship between implementing NTDeliver and its impact on delivery timeliness and other KPIs. Furthermore, the 
data meets the normality of the error distribution assumption for OLS regression. Q-Q plots were used to verify that 
most data is on a distribution lying on approximately on a straight line. While go signal timeliness did not show a 
straight trend, the central limit theorem enables the normality assumption to be met in the case of a “sufficiently large 
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sample,” for which the literature generally notes a sample of >50 would be “robust to violation of the normality 
assumption” [26]. This variable had over 200 samples, thus meeting the central limit theorem condition. While both 
medicine and disease type are included as control variables, these variables are not found to be significantly correlated 
since some medicines treat more than one disease and therefore is not a 1:1 mapping; hence, multi collinearity is not 
a concern. Control variables and robustness checks were applied to strengthen the validity of the results. We 
considered p values less than 0.10 to be statistically significant.
The shipment data extracted from the system covers orders made through December 31, 2018 and was therefore segmented 
in two groups to address the first research question: 1) shipments with POs raised prior to the implementation of NTDeliver 
(February 28, 2006-August 31, 2016) for the “pre” NTDeliver group; 2) shipments with POs raised after the 
implementation of NTDeliver (September 1, 2016-Dec 31, 2018) for the “post” NTDeliver group.  Only the data in the 
“post” group was used to answer the second research question regarding the impact on shipment performance of making 
country-level data publicly accessible. The data in the “post” group was split into two groups, with consideration to 
February 1, 2018, as the implementation date of this publicly accessible data: 1) “Post 1” = 0 for shipments with a PO date 
prior to February 1, 2018 but after August 31, 2016; 2) “Post 2” = 1 for shipments with a PO date equal to or later than 
February 1, 2018 but earlier than January 1, 2019.
Results
We first study the general impact of information sharing through NTDeliver on shipment performance within the NTD 
PC medicines supply chain. The data collected included 1,484 total shipments, with 1,068 shipments classified in the 
“pre” NTDeliver group and 416 in the “post” group. As noted, pairwise deletion was used in cases where data was 
missing, which accounts for the differing number of observations between variables. Table 2 summarizes the 
regression results illustrating the bivariate associations between the implementation of the NTDeliver system and NTD 
supply chain KPIs.
 











NTDeliver 1.01 40.21 0.13 0.53 0.73
p-value (0.000) (0.000) (0.69) (0.09) (0.03)
Predicted direction ↑ ↓ ↑ ↑ ↑
Actual direction ↑ ↑ ↑ NS ↑ ↑
WHO region Yes Yes Yes Yes Yes 
Medicine type Yes Yes Yes Yes Yes 
Disease Yes Yes Yes Yes Yes 
Order size Yes Yes Yes Yes Yes 
Mode of shipment Yes No* Yes Yes Yes 
Observations 1,052 249 636 783 636
NS = non-significant
* Sample size too limited to incorporate variable
Table 2. Regression results showing the relationship between NTD supply chain key performance 
indicators and implementation of information sharing through NTDeliver. 
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Notably, delivery timeliness, the KPI considered most important to measure supply chain performance, shows a 
positive and highly significant impact with a p-value of 0.03. The coefficient, 0.73, indicates a positive improvement 
of a little over half a month against the one-month pre-MDA benchmark. This result suggests information sharing is 
positively associated with earlier delivery of medicines to CMS. PO timeliness and arrival timeliness also demonstrate 
positive and significant results supporting the hypothesized direction, although arrival timeliness is significant at a 
lower confidence level. Information sharing appears to be strongly associated with a one-month improvement in PO 
timeliness, at the 99% confidence level. Arrival timeliness improvement by about half a month seems to also be 
associated with the information sharing, but with a p-value of 0.09 in the 90% confidence level, indicating a lower 
significance than the other performance indicators.
Conversely, the results for go signal timeliness appear to support the null hypothesis. While go signal timeliness is 
highly significant (p<0.01), even though the coefficient value is positive, this actually indicates a negative relationship 
with information sharing due to the calculation method for the variable (calculated as the difference between 
requested and actual go signal date). The coefficient suggests an increase in the difference between the go signal 
request and approval of about 40 days. Because there is no perceivable standard for establishing this request date and 
it is defined per request of the pharmaceutical manufacturer and any supporting partners, additional analysis provides 
further insight into how the go signal timeliness calculation may have changed after NTDeliver was implemented. 
Particularly, the pharmaceutical manufacturer may have started to provide earlier request dates, due to increased 
pressure to ensure on-time delivery after NTDeliver implementation. 
Dependent variable Difference between PO date and go signal 
request date (in days)
Difference between go signal approved date and 
shipment date (in days)
NTDeliver - 48.86 - 50.89
p-value 0.000 0.000
WHO region Yes Yes 
Medicine type Yes Yes 
Disease Yes Yes 
Order size Yes Yes 
Mode of shipment No* No*
Observations 263 263
* Sample size too limited to incorporate variable
Table 3. Bivariate association between regression results showing the relationship between 
implementation of information sharing through NTDeliver and key differences between go signal dates
These results provided indicate that the difference between PO date and go signal request date has significantly 
decreased, since the coefficient is negative (Table 3). This may indicate that since the implementation of information 
sharing through NTDeliver, go signal requests dates provided by the pharmaceutical manufacturer were earlier dates 
relative to the PO date. Also, the results indicate a significant reduction in the number of days between the go signal 
approved date and the shipment date since NTDeliver was implemented, indicating potentially that pharmaceutical 
manufacturers shipped medicines more quickly after the go signal was provided. 
Next, we study the impact of making country-level data publicly accessible and particularly promoting this data access to 
country program managers. Specifically, three sessions were conducted in 2018 to support publicizing the release NTD 
supply chain data to a country program manager audience: 1) an informational session at the program manager meeting 
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in Kigali, Rwanda; 2) a webinar in the Pan American Health Organization (PAHO) region, and 3) a webinar hosted by 
ENVISION attended by country program managers from various regions. The hypothesis is that extending information 
sharing may have a positive impact for the following processes, because they are actively displayed in the public country 
pages, providing direct access for program managers to follow-up on status: shipment timeliness, arrival timeliness, and 
delivery timeliness. Table 4 provides the analysis results to answer the second research question regarding the impact 
of making country-level data publicly accessible. 










NTDeliver public access 0.33 - 14.88 2.57 2.88 2.82
p-value 0.49 0.42 0.001 0.003 0.01
Predicted direction NS NS ↑ ↑ ↑
Actual direction ↑NS ↓NS ↑ ↑ ↑
WHO region Yes Yes Yes Yes Yes 
Medicine type Yes No* Yes Yes Yes 
Disease Yes Yes Yes Yes Yes 
Order size Yes Yes Yes Yes Yes 
Mode of shipment Yes No* Yes Yes Yes
Observations 387 132 296 262 255
NS=non-significant
*Sample size too limited to incorporate variable
Table 4. Regression results showing the relationship between implementation of publicly accessible 
country-level data through NTDeliver and NTD supply chain key performance indicators
The results show three variables with significant, positive correlation: shipment timeliness, arrival timeliness, and 
delivery timeliness—consistent with the hypothesis that these variables would be impacted since they are actively 
displayed in these publicly accessible pages. In the main regression results, shipment timeliness did not show any 
significance from the information sharing. In these results, shipment timeliness is the most significant variable at a 
p-value of 0.001 and with a substantial coefficient of 2.57, suggesting that while information sharing alone did not 
have any significant impact on this process, implementing the publicly accessible country pages appears to be 
impactful enough to significantly improve shipment timeliness by 2.5 months. For both arrival timeliness and delivery 
timeliness, which were also significant in the main regression results, the coefficients are substantially larger than in 
the main results and the p-values are substantially lower than those in the main regression results. Arrival timeliness 
in the main results was just on the cusp between being significant and non-significant, with a p-value of 0.09 in the 
90% confidence level. In these results, arrival timeliness is significant with a p-value of 0.003. Also, the coefficient 
increases from 0.53 to 2.88, a marked improvement as well. Similarly, the important delivery timeliness performance 
indicator has a p-value of 0.011 in these results, compared to the main results in which the p-value was 0.03. The 
coefficient is 2.82, compared to the main results coefficient 0.73—indicating an improvement by over two months 
from the main results. These results suggest that while information sharing positively impacts arrival and delivery 
timeliness, increasing visibility of the country performance furthers the positive impact to the supply chain, 
particularly to downstream processes. 
We also conducted further analyses to check the robustness of the results. First, we re-ran the regression accounting for a 
lag in impact from information sharing. The analysis revealed that that all dependent variables, except arrival timeliness, 
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remain significant and generally consistent with the main results when accounting for a six-month theoretical “lag 
time to benefit,” considered as the time between implementing the intervention and observing improved outcomes.27 
Additionally, we conducted a “double pretest” to test the validity of the “pre” group as comparison. This “double pretest” 
was used as a validity check to ensure that merely “history” and/or “maturation” is not the reason for the differences 
between the pretest and posttest results, rather than independent variable [28]. The pretest group was divided and 
compared for significant differences in performance to assure any differences in performance within the pretest group 
are minimal and/or less than the difference between the pretest and posttest groups. The groups were divided with 
roughly the same number of shipments in each group, with one group comprised of shipments with POs raised between 
2006-2013 and the other with POs raised between 2014-2016 August. The results from this analysis indicated that 
only PO timeliness had a positive, significant difference between these two pretest groups. No other dependent 
variables have an observable difference in performance.
Discussion
Lack of coordination and limited transparency are two top issues in humanitarian supply chains [29]. Although 
existing literature on for-profit supply chains suggests addressing the issues though information sharing, it is unclear 
whether and how information sharing can improve performance in the non-profit humanitarian context [10-13]. In 
this paper, we examined the impact of information sharing on humanitarian supply chain performance. This paper 
contributes to the small body of literature exploring humanitarian supply chain performance. Our analysis is the first 
to undertake an empirical study evaluating performance and information sharing both in the context of the NTD 
supply chain and in the broader humanitarian space. While most existing literature focuses on information sharing in 
for-profit supply chains, which is typically focused on sharing information between the buyer and supplier, this paper 
addresses the gap by investigating the impact of sharing information publicly for non-profit supply chains. The results 
of our study demonstrate the value of investment in supply chain performance measurement and information sharing 
towards the success of global health partnerships and such initiatives may be implemented in the broader context of 
humanitarian programs.
We find that information sharing is positively associated with the timeliness of several key stages in NTD supply 
chain, i.e., PO timeliness, arrival timeliness, and shipment timeliness, and consequently, the key success measure for 
the NTD supply chain—delivery timeliness. Furthermore, when detailed country-level data was shared with and 
promoted to NTD program managers in different countries, these timeliness measures improved even more. The 
impact of information sharing appears to be more significant when the information is released publicly and 
particularly promoted to country program managers, compared to when it is shared only with the supply chain partners 
(i.e., WHO and pharmaceutical donors).  This observation may imply that it is more effective to share information 
with those accountable for successful outcomes and performance from the work, rather than only with those driving 
and directing the work.
The robustness checks also showed that even if the information sharing effect took time to make an impact, the 
performance still improved and can be attributed more confidently to implementation of NTDeliver. Furthermore, 
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although there is no “control group” in our research design, we conduct a “double pretest” to investigate if other 
observed time-varying variables may contribute to the significant results. Comparison with performance before the 
information sharing was implemented suggests that the supply chain performance does not simply improve over time, 
with exception to one performance indicator. Only PO timeliness indicates a significant positive change over time 
during the period before NTDeliver was implemented. The reason for this change in PO timeliness may be attributed 
to a process change coinciding around the timing of the second pretest group defined in this analysis, which included 
medicines ordered from 2014 onward: the JAP was implemented by the WHO in 2013 to standardize processes to 
support an integrated application submission and review for donated medicines [23]. This JAP process most positively 
impacts the PO process as it promoted more coordination between the various levels of WHO offices to assure timely 
applications and order fulfillment for donated medicines [23].
This research has some limitations that may naturally inform future research. The quasi-experimental design used 
lacks a control group and random assignment since NTDeliver was implemented for all PC medicine donations 
managed through the NTD Supply Chain Forum [30]. Although we used a “double pretest” robustness check to verify 
our results, future research could study the impact of information sharing in a controlled setting. Furthermore, there 
is a growing desire for financial donors to understand the impact of investments from an outcomes perspective, 
especially in the interest of funding effective health innovations that offer value for money [31].While our research 
results certainly helps to validate the positive and measurable impact of the information sharing intervention on the 
supply chain, further research on how the supply chain performance improvements result in a reduction in delayed 
and/or missed MDAs would provide more perspectives on linking the delivery timeliness improvements to number 
of additional individuals reached. Lastly, with respect to the current global health climate, the COVID-19 pandemic 
had a significant impact on NTD programs, with the WHO recommending postponing MDAs to respect public health 
measures that advocate for physical distancing to slow the spread of the virus.32 Further research is needed to gain 
insight on new challenges from these disruptions to understand the impact by region and how information sharing 
may help to mitigate such disruption. Also, the data may potentially identify best practices that can provide insight 
on managing uncertainty for global health campaign supply chain planning during a pandemic.
Our results have important practical implications. As the global health aid landscape is becoming more focused on 
driving measurable performance and impact from investments, these findings support investing in supply chain 
systems and commitment to data transparency. Given the relationship between first mile supply chain performance 
and timeliness of MDAs, investment in supply chain information sharing is worthwhile to support improvements to 
NTD program management [7]. As the deadline approaches for achieving the 2030 targets set out in the new WHO 
roadmap and the relevant NTD goals in target 3.3 of the Sustainable Development Goals, there is a high degree of 
confidence that these results affirm that investment in supply chain information sharing is a critical to ensuring 
success. In fact, the new WHO roadmap dedicates an entire section to “Access and logistics,” in which supply chain 
management priorities for improvement are outlined under the umbrella concept that “effective supply chain 
management is vital to ensuring access to quality-assured NTD medicines and other products” [33]. Furthermore, the 
findings imply the benefits of information sharing are potentially maximized when extending information sharing to 
a broader audience, particularly focusing on program managers. Incorporating visibility to upstream data, such as 
attaching country applications or tracking the regional office approval date, may improve these processes as well.  
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Such upstream processes have been noted as potentially impacting delivery timeliness by the WHO HQ—such as the 
fairly significant time taken for the regions to review applications—and further incorporation of these processes in 
NTDeliver may benefit the end-to-end NTD supply chain [7].
Given the significant volume of medicines and the number of people requiring these medicines, the research 
implications have the potential to impact global health programs affecting the health of tens to hundreds of millions 
of people. The research supports that, even in absence of financial remuneration, information sharing contributes 
measurable supply chain improvements and supports investing further in performance measurement in humanitarian 
supply chains. Beyond the NTD space, data transparency is generally viewed as a challenge with country governments 
citing national sovereignty and privacy in refusing to release data for public consumption [34]. Positive results from 
extending the information sharing argue in favor of the value and benefits of information sharing in the global health 
space. As the profile and importance of the supply chain continues to elevate in humanitarian programs, especially 
those in the healthcare space, there will be an opportunity to invest further in such performance measurement tools 
to bring more evidence-based approaches to decision making. This has significant potential to promote accountability 
and coordination resulting in goals achieved and improved health outcomes.
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Appendix
Table A1. Dummy coding matrices
Dummy coding for medicine control variable    
Dummy variable coding
X1X2X3
Categories of original variable
M1 M2 M3
Description of dummy variable
Med2 1 0 0 1 = Med2, 0 = otherwise
Med3 0 1 0 1 = Med3, 0 = otherwise
Med4 0 0 1 1 = Med4, 0 = otherwise
Med1 0 0 0 All 0’s = Med 1
Dummy coding for region control variable 
Dummy Variable Coding
X1X2X3 X4 X5Categories of Original Variable
R1 R2 R3 R4 R5
Description of Dummy Variable
AMRO 1 0 0 0 0 1 = Region1, 0 = otherwise
EMRO 0 1 0 0 0 1 = Region2, 0 = otherwise
EURO 0 0 1 0 0 1 = Region3, 0 = otherwise
SEARO 0 0 0 1 0 1 = Region4, 0 = otherwise
WPRO 0 0 0 0 1 1 = Region5, 0 = otherwise
AFRO 0 0 0 0 0
Dummy coding for disease control variable 
Dummy Variable Coding
X1X2Categories of Original Variable
D1 D2
Description of Dummy Variable
Disease1 1 0 1 = Disease1, 0 = otherwise
Disease2 0 1 1 = Disease2, 0 = otherwise
Disease0 0 0
Dummy coding for order size control variable 
Dummy Variable Coding
X1X2X3
Categories of Original Variable
T1 T2
Description of Dummy Variable
10m > X ≥ 3m 1 0 1 = order size 10m > X ≥ 3m
0 = otherwise
X < 3m 0 1 1 = order size X <3m
0 = otherwise
X ≥ 10m 0 0
Dummy coding for shipment mode control variable 
Dummy Variable Coding
X1X2
Categories of Original Variable
S1 S2
Description of Dummy Variable
Sea 1 0 1 = sea, 0 = otherwise
Land 0 1 1 = land, 0 = otherwise
Air 0 0
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Table A2. Full linear regression results
















(Constant) -1.666 .563 -2.958 .003 -2.771 -.561
Pre vs Post SCPMS 1.012 .288 .107 3.517 .000 .447 1.576
R1 - Region Dummy 2.056 .597 .111 3.445 .001 .885 3.228
R2 - Region Dummy .931 .690 .042 1.349 .178 -.424 2.285
R3 - Region Dummy 1.671 1.241 .042 1.346 .179 -.765 4.106
R4 - Region Dummy .989 .434 .096 2.278 .023 .137 1.841
R5 - Region Dummy 2.277 .467 .174 4.880 .000 1.361 3.192
M1 - Medicine Dummy .889 .465 .065 1.910 .056 -.024 1.802
M2 - Medicine Dummy 1.363 .510 .093 2.675 .008 .363 2.364
D1 - Disease Dummy 1.315 .456 .103 2.884 .004 .420 2.210
D2 - Disease Dummy -.575 .384 -.061 -1.498 .134 -1.329 .178
T1 - Tablets Dummy .210 .399 .022 .527 .598 -.572 .993
T2 - Tablets Dummy -.118 .542 -.012 -.217 .828 -1.180 .945
S1 - Shipment Dummy .968 .430 .106 2.250 .025 .124 1.813
S2 - Shipment Dummy -.598 .642 -.045 -.932 .351 -1.857 .661














(Constant) -41.228 19.823 -2.080 .039 -80.281 -2.176
Pre vs Post SCPMS 40.215 9.473 .285 4.245 .000 21.552 58.878
R1 - Region Dummy 31.881 14.162 .159 2.251 .025 3.981 59.782
R2 - Region Dummy 12.564 15.933 .053 .789 .431 -18.827 43.954
R3 - Region Dummy 31.065 20.544 .102 1.512 .132 -9.409 71.539
R4 - Region Dummy 14.793 17.188 .060 .861 .390 -19.069 48.654
R5 - Region Dummy 12.148 16.392 .049 .741 .459 -20.145 44.441
M1 - Medicine Dummy 45.173 69.246 .041 .652 .515 -91.249 181.596
M2 - Medicine Dummy 28.218 13.296 .174 2.122 .035 2.023 54.413
D1 - Disease Dummy 12.006 14.108 .068 .851 .396 -15.789 39.801
D2 - Disease Dummy -28.379 13.125 -.200 -2.162 .032 -54.237 -2.521
T1 - Tablets Dummy 11.055 15.150 .078 .730 .466 -18.792 40.902
T2 - Tablets Dummy 22.821 18.051 .155 1.264 .207 -12.741 58.383
S1 - Shipment Dummy 26.610 13.236 .185 2.010 .046 .534 52.686
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Lower Bound Upper Bound
(Constant) -2.794 .653 -4.280 .000 -4.075 -1.512
Pre vs Post SCPMS .132 .326 .016 .404 .686 -.509 .772
R1 - Region Dummy 2.190 .660 .132 3.318 .001 .894 3.486
R2 - Region Dummy .008 .728 .000 .011 .991 -1.421 1.437
R3 - Region Dummy .489 1.186 .016 .412 .681 -1.841 2.818
R4 - Region Dummy .187 .496 .019 .378 .706 -.786 1.161
R5 - Region Dummy 2.547 .520 .207 4.898 .000 1.526 3.568
M1 - Medicine Dummy 3.440 .978 .139 3.518 .000 1.520 5.361
M2 - Medicine Dummy 2.922 .489 .267 5.980 .000 1.962 3.882
D1 - Disease Dummy -.188 .544 -.015 -.345 .730 -1.255 .880
D2 - Disease Dummy -.543 .404 -.066 -1.343 .180 -1.338 .251
T1 - Tablets Dummy .420 .444 .051 .945 .345 -.453 1.293
T2 - Tablets Dummy .185 .649 .020 .285 .776 -1.090 1.460
S1 - Shipment Dummy .195 .489 .024 .398 .691 -.766 1.156
S2 - Shipment Dummy 1.917 .753 .141 2.545 .011 .438 3.396





95.0% Confidence Interval for 
B
Model
B Std. Error Beta
t Sig.
Lower Bound Upper Bound
(Constant) -.898 .611 -1.470 .142 -2.097 .301
Pre vs Post SCPMS .534 .312 .060 1.714 .087 -.078 1.146
R1 - Region Dummy 1.442 .637 .083 2.264 .024 .191 2.692
R2 - Region Dummy -.275 .757 -.013 -.364 .716 -1.762 1.211
R3 - Region Dummy .828 1.222 .024 .677 .499 -1.572 3.227
R4 - Region Dummy .787 .456 .078 1.728 .084 -.107 1.682
R5 - Region Dummy 1.942 .475 .167 4.088 .000 1.009 2.874
M1 - Medicine Dummy 1.539 .512 .118 3.004 .003 .533 2.544
M2 - Medicine Dummy 2.812 .502 .226 5.607 .000 1.828 3.797
D1 - Disease Dummy -.329 .481 -.028 -.685 .493 -1.273 .614
D2 - Disease Dummy -.618 .402 -.073 -1.538 .124 -1.408 .171
T1 - Tablets Dummy .253 .426 .030 .595 .552 -.583 1.089
T2 - Tablets Dummy -.317 .618 -.034 -.512 .609 -1.529 .896
S1 - Shipment Dummy -.687 .463 -.082 -1.483 .139 -1.597 .223
S2 - Shipment Dummy .797 .725 .056 1.100 .272 -.626 2.220
.CC-BY 4.0 International licenseavailable under a
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprint (whichthis version posted June 3, 2021. ; https://doi.org/10.1101/2021.06.03.446886doi: bioRxiv preprint 
21












Lower Bound Upper Bound
(Constant) -2.012 .698 -2.881 .004 -3.383 -.640
Pre vs Post SCPMS .727 .338 .083 2.150 .032 .063 1.391
R1 - Region Dummy 1.698 .730 .094 2.326 .020 .264 3.131
R2 - Region Dummy -.189 .763 -.010 -.247 .805 -1.687 1.310
R3 - Region Dummy 2.960 1.502 .077 1.971 .049 .011 5.909
R4 - Region Dummy .359 .534 .034 .673 .501 -.689 1.407
R5 - Region Dummy 2.142 .545 .175 3.933 .000 1.072 3.211
M1 - Medicine Dummy 3.561 1.054 .134 3.379 .001 1.491 5.631
M2 - Medicine Dummy 2.627 .526 .225 4.991 .000 1.594 3.661
D1 - Disease Dummy -.220 .514 -.019 -.428 .669 -1.230 .789
D2 - Disease Dummy .036 .438 .004 .081 .935 -.825 .896
T1 - Tablets Dummy .436 .469 .050 .930 .353 -.485 1.358
T2 - Tablets Dummy .169 .681 .018 .249 .804 -1.168 1.507
S1 - Shipment Dummy -.908 .510 -.105 -1.780 .076 -1.909 .094
S2 - Shipment Dummy .723 .780 .055 .927 .354 -.808 2.254
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Table A3. Robustness check results














NTDeliver 0.999 38.495 - 0.026 0.204 0.741
p-value 0.002 0.000 0.937 0.553 0.046
WHO region Yes Yes Yes Yes Yes 
Medicine type Yes Yes Yes Yes Yes 
Disease Yes Yes Yes Yes Yes 
Order size Yes Yes Yes Yes Yes 
Mode of 
shipment Yes No* Yes Yes Yes
Observations 970 226 569 715 567
*Sample size too limited to incorporate variable














NTDeliver 1.42 -30.476 0.991 0.581 0.173
p-value 0.000 0.293 0.215 0.203 0.818
WHO region Yes Yes Yes Yes Yes 
Medicine type Yes Yes Yes Yes Yes 
Disease Yes Yes Yes Yes Yes 
Order size Yes Yes Yes Yes Yes 
Mode of 
shipment Yes No* Yes Yes Yes
Observations 664 117 339 520 380
*Sample size too limited to incorporate variable
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